Abstract:Transforming growth factor-β (TGF-β), an important cytokine that plays a key role in many diseases regulates a wide array of cellular and physiologic processes via several TGF-β-driven signaling cascades, including the SMAD and non-SMAD-driven pathways. However, the detailed mechanisms by which TGF-β induces such diverse responses remain poorly understood. In particular, compared to the SMAD-dependent pathway, SMAD-independent pathways such as the ERK/MAPK pathway, which is critical in cancer progression, are less characterized. Here, we develop an integrated mechanistic model of the TGF-β-triggered ERK activation pathway and its crosstalk with the SMAD pathway, an analysis of which demonstrates how SMAD dynamics can be significantly modulated and regulated by the ERK pathway. In particular, SMAD-mediated transcription can be altered and delayed due to expedited phosphorylation of the linker of SMAD by TGF-β-activated ERK; and enhanced ERK activity, but attenuated SMAD activity, can be achieved simultaneously by fast turnover of TGF-β receptors via lipid-rafts. Also, in silico mutations of the TGF-β pathways reveal that the dynamic characteristics of both SMAD and ERK signaling may change significantly during cancer development. Specifically, normal cells may exhibit enhanced and sustained SMAD signaling with transient ERK activation, whereas cancerous cells may produce elevated and prolonged ERK signaling with enervated SMAD activation. These distinctive differences between normal and cancerous signaling behavior provide clues concerning, and potential explanations for, the seemingly contradictory roles played by TGF-β during cancer progression. We demonstrate how crosstalk among various branch pathways of TGF-β can influence overall cellular behavior. Based on model analysis, we hypothesize that aberrant molecular alterations drive changes in the intensity and duration of SMAD and ERK signaling during cancer progression and ultimately lead to an imbalance between the SMAD and ERK pathways in favor of tumor promotion. Thus, to treat cancer patients with a genetic signature of oncogenic Ras effectively may require at least a combination therapy to restore both the expression of TGF-β receptors and the GTPase activity of Ras.

TGF-β receptor I/II trafficking and signaling at primary cilia are inhibited by ceramide to attenuate cell migration and tumor metastasis

Intracrine Vegf Signalling Mediates Colorectal Cancer Cell Migration and Invasion

TACE-Mediated Ectodomain Shedding of the Type I TGF-b Receptor Downregulates TGF-b Signaling

TACE-Mediated Ectodomain Shedding of the Type I TGF-β Receptor Downregulates TGF-β Signaling

The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-imidazolide alters transforming growth factor beta-dependent signaling and cell migration by affecting the cytoskeleton and the polarity complex

Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid

The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42

Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling

Monoubiquitination of p120-catenin is essential for TGF-induced epithelial-mesenchymal transition and tumor metastasis

MicroRNA-182 Targets SMAD7 to Potentiate TGFβ-induced Epithelial-Mesenchymal Transition and Metastasis of Cancer Cells.

TSC1 and TSC2 regulate cilia length and canonical Hedgehog signaling via different mechanisms

Data from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Sec3 Knockdown Inhibits TGF-β Induced Epithelial-Mesenchymal Transition Through the Down-Regulation of Akt Phosphorylation in A549 Cells.

Computational Modeling and Analysis of the TGF-β-induced ERK and SMAD Pathways

CERS6 required for cell migration and metastasis in lung cancer

Actin Cytoskeleton Regulation of Epithelial Mesenchymal Transition in Metastatic Cancer Cells

C-Met Activation Leads to the Establishment of a TGFβ-receptor Regulatory Network in Bladder Cancer Progression

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.

Resistance to transforming growth factor–beta occurs in the presence of normal Smad activation

The Snail signaling branch downstream of the TGF-β/Smad3 pathway mediates Rho activation and subsequent stress fiber formation

Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response